Hypothesis

We hypothesize that baseline pressure pain sensitivity (lower threshold) predicts accelerated epigenetic aging over a 2‑year follow‑up, and that this relationship is mediated by age‑related decline in Leydig cell testosterone production driven by mitochondrial dysfunction and reduced StAR‑mediated cholesterol flux.

Mechanistic Rationale

1. Pain sensitivity reflects the efficacy of descending pain modulatory systems, which depend on opioid and non‑opioid tone that is upregulated by testosterone.[5][6]
2. Testosterone synthesis in Leydig cells requires cholesterol transport into mitochondria via the StAR protein; mitochondrial oxidative phosphorylation fuels this step.[9]
3. With aging, Leydig cell mitochondria accumulate damage, limiting ATP and increasing ROS, which diminishes StAR activity and testosterone output.[10]
4. Lower testosterone reduces central analgesic tone, lowering pain thresholds and increasing perceived sensitivity.
5. Simultaneously, diminished steroid signaling lifts inhibition on NF‑κB pathways, fostering low‑grade inflammation that drives epigenetic aging clocks (DNAmPhenoAge, DNAmGrimAge).[1][2]

Thus, pain sensitivity is a functional read‑out of Leydig cell mitochondrial health and steroidogenic capacity, linking perception to systemic biological age.

Testable Predictions

• In a cohort of men aged 40‑70, baseline pressure pain threshold (algometry) will inversely correlate with serum total testosterone and positively correlate with circulating mitochondrial DNA (cell‑free mtDNA) as a marker of mitophagy.
• Individuals in the lowest pain‑threshold quartile will show a greater increase in DNAmPhenoAge after 24 months than those in the highest quartile, even after adjusting for baseline age, BMI, and comorbidities.
• Statistical mediation analysis will reveal that change in testosterone accounts for ≥30 % of the effect of baseline pain sensitivity on epigenetic age change, while change in StAR‑related exosomal miRNA (e.g., miR‑1246) accounts for an additional 15 %.
• Experimental manipulation: acute testosterone suppression with a GnRH antagonist in young healthy volunteers will transiently lower pressure pain thresholds and raise inflammatory cytokines (IL‑6, TNF‑α) within 48 h, mimicking the aging phenotype.

Falsifiability

If baseline pain sensitivity shows no predictive value for epigenetic age change after controlling for testosterone and mitochondrial markers, or if testosterone replacement does not normalize pain thresholds in low‑threshold older men, the hypothesis is refuted.

Methods Overview

• Recruit 300 community‑dwelling men, measure pressure pain threshold (kg) using a handheld algometer at the trapezius.
• Collect fasting blood for serum testosterone, LH, cell‑free mtDNA, exosomal StAR mRNA/miRNA, cytokines, and epigenome‑wide DNA methylation (Illumina EPIC).
• Repeat assessments at 12 and 24 months.
• Use linear mixed models for longitudinal epigenetic age trajectories; mediation analysis with bootstrapped confidence intervals.

By integrating pain phenotyping with testicular mitochondrial‑steroid biomarkers, this work could yield a low‑cost, functional assay that outperforms current epigenetic clocks in tracking biological aging.